NCT00074022View on ClinicalTrials.gov

GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

November 30, 2007

Conditions

Recurrent Non-small Cell Lung CancerRecurrent Prostate CancerStage III Prostate CancerStage IIIA Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung CancerStage IV Prostate CancerUnspecified Adult Solid Tumor, Protocol Specific

Interventions

BIOLOGICAL

GTI-2040

Given IV

DRUG

docetaxel

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

Trial Locations (1)

M5G 2M9

Princess Margaret Hospital Phase 2 Consortium, Toronto

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00074022 - GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors | Biotech Hunter | Biotech Hunter